Gyre Therapeutics GYRE Institutional Ownership

Updated Oct 10, 2026

Gyre Therapeutics, Inc. (NASDAQ:GYRE) appeared in the 13F filings of 61 institutional investors for the quarter ended June 30, 2026.

• These investors held 8.17% of outstanding shares in Q2 2026, up from 3.73% the quarter before.
• Total shares held in Gyre Therapeutics rose 154.35% from Q1 2026, while the number of holders rose 32.61% from Q2 2025.
• Among the 61 holders of Gyre Therapeutics, 43 added to their positions, 10 reduced their stakes and 8 left their positions unchanged.
• Institutional investors held 8.67Mn shares of Gyre Therapeutics in total at the end of Q2 2026, up 5.26Mn from the prior quarter and up 5.29Mn from a year earlier.
• HSG Holding Ltd led 13F holders of GYRE with 3.75Mn shares as of June 30, 2026, or 3.54% of shares outstanding.
• The biggest increases in GYRE positions during Q2 2026 came from BlackRock, Inc. (+235.31K shares), Geode Capital Management, LLC (+101.54K shares), Vanguard Portfolio Management LLC (+54.14K shares), Northern Trust Corp (+35.7K shares) and Morgan Stanley (+33.05K shares).
• The largest position reductions in GYRE for Q2 2026 were by Vanguard Capital Management LLC (-107.28K shares), SBI Securities Co., Ltd. (-4.09K shares), FMR LLC (-3.74K shares), Tower Research Capital LLC (-3.29K shares) and UBS Group AG (-2.32K shares).
• Per Business Quant data, the 10 largest holders of Gyre Therapeutics at the end of Q2 2026 were HSG Holding Ltd (3.75Mn shares), BlackRock, Inc. (993.94K shares), Octagon Capital Advisors LP (954.42K shares), Vanguard Capital Management LLC (876.93K shares), Geode Capital Management, LLC (532.95K shares), State Street Corp (245.4K shares), Charles Schwab Investment Management Inc (184.29K shares), Northern Trust Corp (169.54K shares), SBI Securities Co., Ltd. (166.75K shares) and Vanguard Fiduciary Trust Co (151.07K shares).